Synergistic effect of fenretinide and curcumin for treatment of non-small cell lung cancer

Chen, Huanxian; Chen, Linmin; Wang, Liang; Zhou, Xinhua; Chan, Judy Yuet-Wa; Li, Jingjing; Cui, Guozhen; Lee, Simon Ming‐Yuen

doi:10.1080/15384047.2016.1219810

Cited by 14 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[15][16][17][18] Because curcumin has a variety of properties, the combination of curcumin with a single target or pathway drug is generally more effective compared with a single targeted drug alone. 19,20 Considering that curcumin has significant varieties of biological activities, along with low toxicity, affordability, and easy synthesis, curcumin fulfills the characteristics for an ideal lead compound in the development of new agents for the treatment of a variety of diseases, especially a variety of malignancies. [21][22][23] Due to the low bioactivity and availability of curcumin, it is limited for the clinical treatment of tumors, therefore there is a need to develop more effective curcumin analogs to inhibit proliferation, metastasis, and invasion of tumor cells at lower doses, as a more effective cancer treatment.…”

Section: Discussionmentioning

confidence: 99%

Curcumin analog B14 has high bioavailability and enhances the effect of anti‐breast cancer cells in vitro and in vivo

Shen

Pan

et al. 2020

Cancer Science

View full text Add to dashboard Cite

Curcumin has a variety of anticancer properties, but low bioavailability prevents its use in chemotherapeutic applications. To address this problem, we tested the efficacy of the synthetic curcumin analog B14 in breast cancer cells and explored the mechanism by which B14 inhibits proliferation and metastasis of breast cancer cells. We used the breast cancer cell line MCF‐7, MDA‐MB‐231 to study the anticancer effects of B14 and assessed cell viability, cell migration and invasion, cell cycle, and apoptosis, in addition, the antitumor effect of B14 in vivo was examined in mice bearing MDA‐MB‐231 cells. We found that, as the concentration of B14 increased, cell viability decreased in a dose‐dependent manner. Compound B14 exerted the best antitumor activity and selectivity for MCF‐7 and MDA‐M‐231 cells (IC50 = 8.84 μmol/L and 8.33 μmol/L, respectively), while its IC50 value for MCF‐10A breast epithelial cells was 34.96 μmol/L. B14 has been shown to be a multi‐targeted drug that alters the expression of cyclin D1, cyclin E1, and cyclin‐dependent kinase 2 (CDK2), and ultimately induces G1 phase cell cycle arrest. At the same time, B14 activates the mitochondrial apoptosis pathway in breast cancer cells. Furthermore, B14 was more effective than curcumin in inhibiting cell migration, invasion, and colony formation. In tumor‐bearing mice, analog B14 significantly reduced tumor growth and inhibited cell proliferation and angiogenesis. The pharmacokinetic test found that B14 was more stable than curcumin in vivo. Our data reveal the therapeutic potential of the curcumin analog B14 and the underlying mechanisms to fight breast cancer cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Curcumin analog B14 has high bioavailability and enhances the effect of anti‐breast cancer cells in vitro and in vivo

Shen

Pan

et al. 2020

Cancer Science

View full text Add to dashboard Cite

show abstract

“…In addition, Cur plus interferon-α could reverse interferon-α-induced NF-κB and COX-2 activation, suggesting that Cur counterbalances the negative effects of interferon-α and improves its antitumor activity [ 98 ]. Moreover, Cur improves the cytotoxicity of fenretinide in NSCLC by governing the expression of the ER chaperone protein GRP78 [ 101 ]. Finally, co-treatment with Cur plus multiple small molecular antagonists, such as AG1024, PD173074, LY294002, or caffeic acid phenethyl ester, also improves proliferation suppression in NSCLC by blocking the corresponding signaling pathway [ 102 ].…”

Section: The Combination Of Cur and Some Small Molecular Compounds In...mentioning

confidence: 99%

Curcumin and Its Analogs in Non-Small Cell Lung Cancer Treatment: Challenges and Expectations

et al. 2022

View full text Add to dashboard Cite

Researchers have made crucial advances in understanding the pathogenesis and therapeutics of non-small cell lung cancer (NSCLC), improving our understanding of lung tumor biology and progression. Although the survival of NSCLC patients has improved due to chemoradiotherapy, targeted therapy, and immunotherapy, overall NSCLC recovery and survival rates remain low. Thus, there is an urgent need for the continued development of novel NSCLC drugs or combination therapies with less toxicity. Although the anticancer effectiveness of curcumin (Cur) and some Cur analogs has been reported in many studies, the results of clinical trials have been inconsistent. Therefore, in this review, we collected the latest related reports about the anti-NSCLC mechanisms of Cur, its analogs, and Cur in combination with other chemotherapeutic agents via the Pubmed database (accessed on 18 June 2022). Furthermore, we speculated on the interplay of Cur and various molecular targets relevant to NSCLC with discovery studio and collected clinical trials of Cur against NSCLC to clarify the role of Cur and its analogs in NSCLC treatment. Despite their challenges, Cur/Cur analogs may serve as promising therapeutic agents or adjuvants for lung carcinoma treatment.

show abstract

“…Fenretinide, a synthetic retinoid acid (RA), has been suggested as a suitable chemotherapy drug in various studies. 103 The combination of fenretinide with curcumin led to enhanced cytotoxic effects and apoptosis in lung cancer cells via downregulation of GRP78, a well-recognized endoplasmic reticulum-chaperone protein. 103 …”

Section: Combined Strategies Utilizing Nanoparticles To Improve Curcumin Applicationmentioning

confidence: 99%

Nanoscale Formulations: Incorporating Curcumin into Combination Strategies for the Treatment of Lung Cancer

Wu¹,

Ou²,

Shang³

et al. 2021

DDDT

View full text Add to dashboard Cite

Lung cancer remains the most common cancer worldwide. Although significant advances in screening have been made and early diagnosis strategies and therapeutic regimens have been developed, the overall survival rate remains bleak. Curcumin is extracted from the rhizomes of turmeric and exhibits a wide range of biological activities. In lung cancer, evidence has shown that curcumin can markedly inhibit tumor growth, invasion and metastasis, overcome resistance to therapy, and even eliminate cancer stem cells (CSCs). Herein, the underlying molecular mechanisms of curcumin were summarized by distinct biological processes. To solve the limiting factors that curtail the clinical applications of curcumin, nanoformulations encapsulating curcumin were surveyed in detail. Nanoparticles, including liposomes, micelles, carbon nanotubes (CNTs), solid lipid nanoparticles (SLNs), nanosuspensions, and nanoemulsions, were explored as proper carriers of curcumin. Moreover, it was firmly verified that curcumin has the ability to sensitize lung cancer cells to chemotherapeutic drugs, such as cisplatin and docetaxel, and to various targeted therapies. Regarding the advantages and drawbacks of curcumin, we concluded that combination therapy based on nanoparticles would be the optimal approach to broaden the application of curcumin in the clinic in the near future.

show abstract

Synergistic effect of fenretinide and curcumin for treatment of non-small cell lung cancer

Cited by 14 publications

References 31 publications

Curcumin analog B14 has high bioavailability and enhances the effect of anti‐breast cancer cells in vitro and in vivo

Curcumin analog B14 has high bioavailability and enhances the effect of anti‐breast cancer cells in vitro and in vivo

Curcumin and Its Analogs in Non-Small Cell Lung Cancer Treatment: Challenges and Expectations

Nanoscale Formulations: Incorporating Curcumin into Combination Strategies for the Treatment of Lung Cancer

Contact Info

Product

Resources

About